Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.37 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.36 |
| ▸ | FABP7 | O15540 | 2/20 | 0.36 |
| ▸ | MDM4 | O15151 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 2/20 | 0.35 |
| ▸ | CASP3 | P42574 | 1/20 | 0.34 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.34 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
| ▸ | PPARA | Q07869 | 1/20 | 0.33 |
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30684530 | 0.91 | EPHX2 (0.41) | EPHX2KMT2AFABP5FABP7CASP3 | |
| SCHEMBL25179560 | 0.90 | PTGIR (0.37) | EPHX2ITGB3ITGA2BKMT2AFABP5 | |
| SCHEMBL29855063 | 0.90 | PTGIR (0.37) | EPHX2ITGB3ITGA2BKMT2AFABP5 | |
| SCHEMBL25178688 | 0.90 | PTGIR (0.37) | EPHX2ITGB3ITGA2BKMT2AFABP5 | |
| SCHEMBL29633721 | 0.90 | PTGIR (0.37) | EPHX2ITGB3ITGA2BKMT2AFABP5 | |
| SCHEMBL25356404 | 0.89 | FABP5 (0.38) | EPHX2ITGB3ITGA2BKMT2AFABP5 | |
| SCHEMBL25356398 | 0.89 | FABP5 (0.38) | EPHX2ITGB3ITGA2BKMT2AFABP5 | |
| SCHEMBL31754272 | 0.89 | MDM4 (0.37) | EPHX2ITGB3ITGA2BKMT2AFABP5 | |
| SCHEMBL29633955 | 0.89 | MDM4 (0.37) | EPHX2ITGB3ITGA2BKMT2AFABP5 | |
| SCHEMBL29633775 | 0.89 | FABP5 (0.38) | EPHX2ITGB3ITGA2BKMT2AFABP5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240400499-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2024-12-05 | — | — | US | claimed |
| US-20240400499-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2024-12-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240400499-A1 | NOVEL AMINO ACID DERIVATIVES | BCAT1, BCAT2, PELP1 | EPHX2 4829/4885ITGB3 4142/4885ITGA2B 3266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.